Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

NYXOAH Stock Over 15% Up So Far On Monday

Loading stream...

(VIANEWS) - Shares of NYXOAH (BEL 20: NYXH.BR) rose by a staggering 15.25% to €9.22 at 14:21 EST on Monday, after five sequential sessions in a row of gains. BEL 20 is jumping 0.14% to €3,843.40, after two successive sessions in a row of gains. This seems, as yet, a somewhat bullish trend trading session today.

NYXOAH's last close was €8.00, 53.27% below its 52-week high of €17.12.

About NYXOAH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.38.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -23.22%.

Yearly Top and Bottom Value

NYXOAH's stock is valued at €9.22 at 14:21 EST, way under its 52-week high of €17.12 and way above its 52-week low of €4.45.

Moving Average

NYXOAH's value is way higher than its 50-day moving average of €5.66 and way above its 200-day moving average of €6.62.

Volatility

NYXOAH's last week, last month's, and last quarter's current intraday variation average was 4.19%, 1.82%, and 2.32%.

NYXOAH's highest amplitude of average volatility was 4.19% (last week), 2.94% (last month), and 2.32% (last quarter).

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is a negative 26.9% and a negative 78.9%, respectively.

More news about NYXOAH (NYXH.BR).